Full Interactive Multimedia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Full Interactive Multimedia. Real-time updates on events, politics, business and more.

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

May 12, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

United States Astellas Pharma Naoki Okamura Genevieve Neal Perry Drug Administration J Public Health

Source: prnewswire.com

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

May 12, 2023

 VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. today... | June 14, 2023

United States Genevieve Neal Perry Naoki Okamura Astellas Pharma Prnewswire Astellas Pharma Inc Health Qual Life Outcomes

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Full Interactive Multimedia News Today

Astellas' VEOZAH&#x2122; (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

Astellas' VEOZAH&#x2122; (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

Explore More Categories

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause